U.S. RESEARCH ROUNDUP- Aprea Therapeutics, Beyondspring, Cognizant Technology

Sigilon Therapeutics

29/12/2020 07:12

Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Aprea Therapeutics, Beyondspring and Cognizant
Technology Solutions on Tuesday. 
    
  HIGHLIGHTS        
     * Aprea Therapeutics Inc  APRE.O : Baird cuts to neutral from outperform
     * Beyondspring Inc  BYSI.O : Evercore ISI initiates coverage with outperform rating and $30 PT
     * Cognizant Technology Solutions Corp  CTSH.O : Credit Suisse raises PT to $91 from $79
     * Seer, Inc.  SEER.O : JP Morgan initiates coverage with overweight rating; target $75
                
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday.
Stock entries are in alphabetical order.       
     * Amphenol Corp  APH.N : JP Morgan sets neutral rating with target price $138
     * Aprea Therapeutics Inc  APRE.O : Baird cuts target price to $5 from $45
     * Aprea Therapeutics Inc  APRE.O : Baird cuts to neutral from outperform
     * Aprea Therapeutics Inc  APRE.O : JP Morgan cuts target price to $6 from $31
     * Aprea Therapeutics Inc  APRE.O : RBC cuts target price to $10 from $40
     * Aprea Therapeutics Inc  APRE.O : RBC cuts to sector perform from outperform
     * Arcturus Therapeutics Holdings Inc  ARCT.O : Baird cuts target price to $69 from $79
     * Arcturus Therapeutics Holdings Inc  ARCT.O : Baird cuts to neutral from outperform
     * Beyondspring Inc  BYSI.O : Evercore ISI initiates coverage with outperform rating and $30 PT
     * Cognizant Technology Solutions Corp  CTSH.O : Credit Suisse raises PT to $91 from $79
     * Kilroy Realty Corp  KRC.N : Evercore ISI cuts target price to $65 from $66
     * Myovant Sciences Ltd  MYOV.N : JP Morgan raises target price to $38 from $30
     * Seer, Inc.  SEER.O : JP Morgan initiates coverage with overweight rating; target $75
     * Sigilon Therapeutics, Inc.  SGTX.O : Jefferies initiates coverage with buy rating; PT $60
       

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))